JP2015502138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502138A5 JP2015502138A5 JP2014535228A JP2014535228A JP2015502138A5 JP 2015502138 A5 JP2015502138 A5 JP 2015502138A5 JP 2014535228 A JP2014535228 A JP 2014535228A JP 2014535228 A JP2014535228 A JP 2014535228A JP 2015502138 A5 JP2015502138 A5 JP 2015502138A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- fragment
- monoclonal antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 9
- 108010062802 CD66 antigens Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ILPCT/IL2011/000808 | 2011-10-11 | ||
| PCT/IL2011/000808 WO2013054320A1 (en) | 2011-10-11 | 2011-10-11 | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| PCT/IL2012/050402 WO2013054331A1 (en) | 2011-10-11 | 2012-10-10 | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502138A JP2015502138A (ja) | 2015-01-22 |
| JP2015502138A5 true JP2015502138A5 (OSRAM) | 2015-12-03 |
| JP6170926B2 JP6170926B2 (ja) | 2017-07-26 |
Family
ID=48081453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535228A Active JP6170926B2 (ja) | 2011-10-11 | 2012-10-10 | 癌胎児抗原関連細胞接着分子（ｃｅａｃａｍ）に対する抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9771431B2 (OSRAM) |
| EP (2) | EP3360899B1 (OSRAM) |
| JP (1) | JP6170926B2 (OSRAM) |
| KR (1) | KR102189409B1 (OSRAM) |
| CN (1) | CN103987729B (OSRAM) |
| AU (1) | AU2012322272C1 (OSRAM) |
| BR (1) | BR112014008893B1 (OSRAM) |
| CA (1) | CA2851762C (OSRAM) |
| ES (2) | ES2661488T3 (OSRAM) |
| IL (1) | IL231931B (OSRAM) |
| IN (1) | IN2014MN00873A (OSRAM) |
| LT (1) | LT2744829T (OSRAM) |
| PL (2) | PL3360899T3 (OSRAM) |
| RU (1) | RU2650869C2 (OSRAM) |
| WO (2) | WO2013054320A1 (OSRAM) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007063424A2 (en) * | 2005-06-09 | 2007-06-07 | Gal Markel | The modulation of immunity and ceacam1 activity |
| ES2668874T3 (es) * | 2009-04-30 | 2018-05-22 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anticuerpos anti-CEACAM1 y métodos de uso de los mismos |
| EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
| WO2015075710A1 (en) * | 2013-11-25 | 2015-05-28 | Ccam Biotherapeutics Ltd. | Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy |
| CA2930218C (en) | 2013-11-25 | 2020-11-17 | Ccam Biotherapeutics Ltd. | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy |
| WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087099A4 (en) * | 2013-12-23 | 2017-07-19 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| US20160376374A1 (en) * | 2014-01-02 | 2016-12-29 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CA2936962C (en) | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| PL3888674T3 (pl) | 2014-04-07 | 2024-09-23 | Novartis Ag | Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19 |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| BR112016024972B1 (pt) * | 2014-04-27 | 2024-02-20 | Ccam Biotherapeutics Ltd | Anticorpo monoclonal humanizado, polinucleotídeo isolado,plasmídeo, composições farmacêutica e de disgnóstico, usos do dito anticorpo monoclonal humanizado e método in vitro para determinar a expressão de ceacam1 |
| US9753036B2 (en) | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| WO2016120331A1 (de) | 2015-01-28 | 2016-08-04 | Karl Sebastian Lang | Agonistische anti-cd66cd66 antikörper für die antiviralen therapie |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| AU2016215604B2 (en) | 2015-02-02 | 2020-08-13 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US12128069B2 (en) | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| AR105433A1 (es) | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| CA3008102A1 (en) | 2015-12-18 | 2017-06-22 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| EP3393504B1 (en) | 2015-12-22 | 2025-09-24 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| CN107345969A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | 包含afp、gp73和ceacam1的血清标记物在诊断肝脏疾病中的用途 |
| CN107345968A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途 |
| CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| WO2018019380A1 (de) * | 2016-07-28 | 2018-02-01 | Universität Duisburg-Essen | Immunstimulatorische anti-ceacam1-antikörper |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| AU2017368332A1 (en) | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for modulation of CAR-T cells |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| KR102325944B1 (ko) * | 2017-11-30 | 2021-11-12 | 재단법인 목암생명과학연구소 | 항-ceacam1 항체 및 이의 용도 |
| KR102019913B1 (ko) * | 2017-03-24 | 2019-09-09 | 재단법인 목암생명과학연구소 | 항-ceacam1 항체 및 이의 용도 |
| MX2019011124A (es) * | 2017-03-24 | 2019-12-19 | Mogam Inst Biomedical Res | Anticuerpo anti-ceacam1 y uso del mismo. |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| CA3067602A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| CN112204048A (zh) | 2017-12-15 | 2021-01-08 | 朱诺治疗学股份有限公司 | 抗cct5结合分子及其使用方法 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN111971059A (zh) | 2018-01-31 | 2020-11-20 | 细胞基因公司 | 使用过继细胞疗法和检查点抑制剂的组合疗法 |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| AU2019267050B2 (en) * | 2018-05-09 | 2024-09-12 | Good T Cells, Inc. | Epitope of regulatory T cell surface antigen and antibody specifically binding thereto |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| CN110684107B (zh) * | 2018-07-06 | 2021-03-23 | 中国人民解放军第四军医大学 | 抗MG7-Ag的单克隆抗体(MGd1)及其用途 |
| CN110684108B (zh) * | 2018-07-06 | 2021-06-04 | 中国人民解放军第四军医大学 | 抗MG7-Ag的单克隆抗体(CEA37)及其用途 |
| EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
| EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| KR20210104713A (ko) | 2018-11-16 | 2021-08-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법 |
| WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| WO2020118295A1 (en) * | 2018-12-07 | 2020-06-11 | The Brigham And Women's Hospital, Inc. | Humanized and affinity-matured anti-ceacam1 antibodies |
| CN113454120A (zh) * | 2018-12-20 | 2021-09-28 | 阿尔伯特爱因斯坦医学院 | 针对人免疫检查点CEACAM1（CD66a）的拮抗剂抗体及其制剂，试剂盒，和使用方法 |
| KR102166982B1 (ko) * | 2019-01-24 | 2020-10-16 | 가톨릭대학교 산학협력단 | 간암에서 CEACAM1 및 EpCAM의 상관관계 및 이를 이용한 간암 치료효과에 대한 정보를 제공하는 방법 |
| WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| US20220242968A1 (en) * | 2019-06-04 | 2022-08-04 | Biotheus Inc. | Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CA3158635A1 (en) * | 2019-11-07 | 2021-05-14 | Green Cross Corporation | Steric epitope of ceacam1, and anti-ceacam1 antibody, or fragment thereof, that specifically binds to same |
| BR112022009679A2 (pt) | 2019-11-26 | 2022-08-09 | Novartis Ag | Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| EP3909601A1 (en) * | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
| MX2022014573A (es) | 2020-05-19 | 2022-12-15 | G1 Therapeutics Inc | Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos. |
| CN115583987B (zh) * | 2020-06-11 | 2025-02-18 | 中国药科大学 | 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用 |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| CN112028997B (zh) * | 2020-08-04 | 2021-08-13 | 中山大学附属第五医院 | 抗ceacam5纳米抗体 |
| EP4097486A4 (en) * | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM |
| MX2023002041A (es) | 2020-08-20 | 2023-04-27 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para mesotelina. |
| WO2022040470A1 (en) * | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| KR20230048150A (ko) * | 2020-08-21 | 2023-04-10 | 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. | 글리코실화된 ceacam5에 특이적으로 결합하는 항체 |
| WO2022041745A1 (zh) * | 2020-08-28 | 2022-03-03 | 安源医药科技（上海）有限公司 | 针对SARS-CoV-2冠状病毒S蛋白的抗体及其用途 |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| CN116621980B (zh) * | 2020-10-21 | 2025-10-28 | 北京纽安博生物技术有限公司 | 抗ceacam6单域抗体及其融合蛋白和应用 |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| US20240083998A1 (en) * | 2021-01-04 | 2024-03-14 | City Of Hope | Prevention and treatment of steroid-resistant or gut graft-versus-host disease (gvhd) |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| KR20250029137A (ko) | 2022-06-22 | 2025-03-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법 |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| CN119654556A (zh) * | 2022-08-08 | 2025-03-18 | 株式会社先端生命科学研究所 | 检测ceacam1的方法 |
| AR130144A1 (es) | 2022-08-10 | 2024-11-06 | Merck Sharp & Dohme Llc | Proteínas de unión a nkg2d, cd16 y ceacam5 |
| IL320758A (en) * | 2022-11-10 | 2025-07-01 | Famewave Ltd | Antibodies against anti-carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) to inhibit neutrophil extracellular trap (NET)-mediated activities |
| AR131320A1 (es) | 2022-12-13 | 2025-03-05 | Juno Therapeutics Inc | Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024165403A1 (en) | 2023-02-06 | 2024-08-15 | Philogen S.P.A. | Anti-cea antibodies |
| WO2024213096A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Neologics Bioscience Co., Ltd. | Ceacam1-targeting antibodies and uses thereof |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6013772A (en) | 1986-08-13 | 2000-01-11 | Bayer Corporation | Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| DK0654085T3 (da) | 1992-01-23 | 1997-09-22 | Merck Patent Gmbh | Monomere og dimere antistof-fragment-fusionsproteiner |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| WO1996013583A2 (en) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| GB9421405D0 (en) | 1994-10-21 | 1994-12-07 | Dow Chemical Co | Low voc laminating formulations |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| JP4843138B2 (ja) | 1998-04-15 | 2011-12-21 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | Ｔ細胞阻害性受容体組成物およびその使用 |
| DE19852804C1 (de) | 1998-11-16 | 1999-12-23 | Christoph Wagener | Beeinflussung der Angiogenese durch CD66a |
| AU6940700A (en) | 1999-08-26 | 2001-03-19 | Amy P. N Skubitz | Peptides capable of modulating the function of cd66 (ceacam) family members |
| DE10016877A1 (de) | 2000-04-05 | 2001-10-18 | Scintec Diagnostics Gmbh Zug | (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung |
| SE0002835D0 (sv) | 2000-08-07 | 2000-08-07 | Karolinska Innovations Ab | Method and kit for production of monoclonal antibodies |
| US20040214184A1 (en) | 2001-02-28 | 2004-10-28 | Skubitz Keith M | Small peptides capable of modulating the function of cd66 (ceacam) family members |
| US20030022292A1 (en) | 2001-06-07 | 2003-01-30 | Gray-Owen Scott D. | Ligation of CEACAM1 |
| US20060058257A1 (en) | 2001-08-03 | 2006-03-16 | Christoph Wagener | Influencing angiogenesis using CD66a |
| US20030190600A1 (en) | 2002-04-05 | 2003-10-09 | Dana-Faber Cancer Institute | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| US20030211477A1 (en) | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| CU23228A1 (en) | 2002-04-29 | 2007-09-26 | Ct Ingenieria Genetica Biotech | FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME |
| US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
| AU2002332087A1 (en) | 2002-10-08 | 2004-05-04 | Immunomedics, Inc. | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |
| WO2004032857A2 (en) | 2002-10-08 | 2004-04-22 | Immunomedics, Inc. | Antibody therapy |
| WO2005006958A2 (en) | 2003-07-12 | 2005-01-27 | Isis Pharmaceuticals, Inc. | Modulation of ceacam1 expression |
| AU2004292180A1 (en) | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Screening assays and methods of tumor treatment |
| WO2006085961A2 (en) * | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
| WO2007063424A2 (en) | 2005-06-09 | 2007-06-07 | Gal Markel | The modulation of immunity and ceacam1 activity |
| RS55181B1 (sr) * | 2005-12-21 | 2017-01-31 | Amgen Res Munich Gmbh | Farmaceutske kompozicije sa rezistencijom na rastvorljivi cea |
| CA2633756C (en) * | 2005-12-21 | 2015-11-24 | Micromet Ag | Pharmaceutical antibody compositions with resistance to soluble cea |
| WO2008029271A2 (en) | 2006-02-27 | 2008-03-13 | Gal Markel | Ceacam based antibacterial agents |
| PL2562184T3 (pl) | 2007-07-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| EP2208069A4 (en) | 2007-11-05 | 2012-02-01 | Gal Markel | CEACAM1-BASED POINT-OF-CARE CANCER DIAGNOSTIC |
| JP5115561B2 (ja) | 2008-01-17 | 2013-01-09 | 日本電気株式会社 | 無線通信端末、方法、プログラム、記録媒体、および無線通信システム |
| ES2668874T3 (es) * | 2009-04-30 | 2018-05-22 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anticuerpos anti-CEACAM1 y métodos de uso de los mismos |
| CA2768725A1 (en) | 2009-07-21 | 2011-01-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A method of diagnosing cancer |
| AU2010288469A1 (en) * | 2009-08-31 | 2012-03-01 | Roche Glycart Ag | Affinity-matured humanized anti CEA monoclonal antibodies |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| US8256790B2 (en) | 2010-05-26 | 2012-09-04 | William Olen Fortner | Adjustable receiver hitch system |
| CN104011925A (zh) | 2011-12-27 | 2014-08-27 | 株式会社Lg化学 | 锂二次电池及其制备方法 |
| CA3201072A1 (en) | 2012-10-12 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
-
2011
- 2011-10-11 WO PCT/IL2011/000808 patent/WO2013054320A1/en not_active Ceased
-
2012
- 2012-10-10 AU AU2012322272A patent/AU2012322272C1/en not_active Ceased
- 2012-10-10 LT LTEP12840002.5T patent/LT2744829T/lt unknown
- 2012-10-10 ES ES12840002.5T patent/ES2661488T3/es active Active
- 2012-10-10 PL PL17200104.2T patent/PL3360899T3/pl unknown
- 2012-10-10 EP EP17200104.2A patent/EP3360899B1/en active Active
- 2012-10-10 PL PL12840002T patent/PL2744829T3/pl unknown
- 2012-10-10 US US14/350,970 patent/US9771431B2/en active Active
- 2012-10-10 CA CA2851762A patent/CA2851762C/en active Active
- 2012-10-10 BR BR112014008893-4A patent/BR112014008893B1/pt active IP Right Grant
- 2012-10-10 EP EP12840002.5A patent/EP2744829B1/en active Active
- 2012-10-10 JP JP2014535228A patent/JP6170926B2/ja active Active
- 2012-10-10 ES ES17200104T patent/ES2942314T3/es active Active
- 2012-10-10 CN CN201280049869.4A patent/CN103987729B/zh active Active
- 2012-10-10 IN IN873MUN2014 patent/IN2014MN00873A/en unknown
- 2012-10-10 WO PCT/IL2012/050402 patent/WO2013054331A1/en not_active Ceased
- 2012-10-10 KR KR1020147010511A patent/KR102189409B1/ko active Active
- 2012-10-10 RU RU2014118773A patent/RU2650869C2/ru active
-
2014
- 2014-04-03 IL IL231931A patent/IL231931B/en active IP Right Grant
-
2017
- 2017-08-22 US US15/683,087 patent/US20170355781A1/en not_active Abandoned
-
2020
- 2020-09-29 US US17/037,136 patent/US11891453B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502138A5 (OSRAM) | ||
| IL274595B2 (en) | Antibodies specific to beta-tgf | |
| JP2014526898A5 (OSRAM) | ||
| JP2015534579A5 (OSRAM) | ||
| JP2020501531A5 (OSRAM) | ||
| JP2018502060A5 (OSRAM) | ||
| JP2015534577A5 (OSRAM) | ||
| CN118987201A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| ES2990971T3 (es) | Nuevos anticuerpos anti-SIRPa y sus aplicaciones terapéuticas | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2012530496A5 (OSRAM) | ||
| JP2011046732A5 (OSRAM) | ||
| JP2017534256A5 (OSRAM) | ||
| JP2018527919A5 (OSRAM) | ||
| JP2017529838A5 (OSRAM) | ||
| JP2018506277A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| JP2010526028A5 (OSRAM) | ||
| JP2018503380A5 (OSRAM) | ||
| JP2017526370A5 (OSRAM) | ||
| JP2018505177A5 (OSRAM) | ||
| JP2013532968A5 (OSRAM) | ||
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| JP2014502955A5 (OSRAM) | ||
| JP2018510617A5 (OSRAM) |